ImmunityBio Inc's next confirmed earnings release is scheduled for March 2, 2027.
| Earnings Date | 3/2/2027 |
As of September 30, 2026, ImmunityBio Inc has 1.06B shares outstanding.
| Shares Outstanding | 1.06B |
As of September 30, 2026, ImmunityBio Inc maintains a current ratio of 4.27, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -75.91, indicating conservative leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.27 |
| Quick Ratio | 3.96 |
| Debt / Equity | -75.91 |
| Debt / EBITDA | -3.38 |
| Interest Coverage | -2.17 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -196.68, reflecting losses generated across the asset base. The company generates approximately 4.77M in revenue per employee across its workforce of 691.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.66 indicates how many times ImmunityBio Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -196.68 |
| Revenue Per Employee | 4.77M |
| Employee Count | 691.00 |
| Inventory Turnover | 0.66 |
Over the twelve months ended September 30, 2026, ImmunityBio Inc recorded an income tax benefit of -2.28M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -20.04B and -20.04B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -2.28M |
Over the twelve months ended September 30, 2026, ImmunityBio Inc generated 3.30B in revenue and converted that into -20.04B in net income, yielding earnings per share of -19.42. EBITDA reached -4.65B, while operating income came in at -4.95B.
| Revenue | 3.30B |
| Gross Profit | 3.26B |
| Operating Income | -4.95B |
| Pretax Income | -20.04B |
| Net Income | -20.04B |
| EBITDA | -4.65B |
| EBIT | -4.95B |
| Earnings Per Share (EPS) | -19.42 |
As of September 30, 2026, ImmunityBio Inc holds 6.04B in cash and equivalents against 15.70B in total debt, resulting in a net debt position of 14.26B. Total book value stands at -20.70B, with working capital of 5.79B providing operational flexibility.
| Cash & Cash Equivalents | 6.04B |
| Total Debt | 15.70B |
| Net Debt | 14.26B |
| Equity (Book Value) | -20.70B |
| Book Value Per Share | -19.46 |
| Working Capital | 5.79B |
ImmunityBio Inc produced -5.19B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -172.05M in capital expenditures, free cash flow totaled -5.36B - equivalent to -5.20 per share.
| Operating Cash Flow | -5.19B |
| Capital Expenditures | -172.05M |
| Free Cash Flow | -5.36B |
| FCF Per Share | -5.20 |
Over the twelve months ended September 30, 2026, ImmunityBio Inc posted a gross margin of 98.79, reflecting its pricing power and cost economics. The operating margin of -150.16 and net profit margin of -607.79 provide insight into operational efficiency.
| Gross Margin | 98.79 |
| Operating Margin | -150.16 |
| Pretax Margin | -607.89 |
| Profit Margin | -607.79 |
| EBITDA Margin | -141.10 |